Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $340,893.00 in Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 32,466 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $10.50, for a total value of $340,893.00. Following the transaction, the chief financial officer now directly owns 68,317 shares of the company's stock, valued at approximately $717,328.50. The trade was a 32.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Dominic Piscitelli also recently made the following trade(s):

• On Monday, June 23rd, Dominic Piscitelli sold 1,034 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.00, for a total transaction of $10,340.00.
• On Thursday, June 12th, Dominic Piscitelli sold 300 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $3,000.00.
• On Wednesday, June 11th, Dominic Piscitelli sold 2,976 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.01, for a total transaction of $29,789.76.
• On Tuesday, June 10th, Dominic Piscitelli sold 324 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $3,240.00.
• On Monday, June 9th, Dominic Piscitelli sold 300 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.00, for a total value of $3,000.00.
• On Friday, June 6th, Dominic Piscitelli sold 2,600 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.01, for a total value of $26,026.00.

Oric Pharmaceuticals Stock Down 1.5%

NASDAQ:ORIC traded down $0.16 on Friday, hitting $10.35. The stock had a trading volume of 607,696 shares, compared to its average volume of 1,123,051. The company has a fifty day moving average price of $7.05 and a two-hundred day moving average price of $7.70. Oric Pharmaceuticals, Inc. has a 1-year low of $3.90 and a 1-year high of $14.67. The stock has a market cap of $881.60 million, a price-to-earnings ratio of -5.53 and a beta of 1.49.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.09. As a group, analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ORIC has been the subject of several recent research reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Wedbush reiterated an "outperform" rating and issued a $20.00 target price on shares of Oric Pharmaceuticals in a research report on Monday. Oppenheimer decreased their price target on shares of Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $21.00 price objective on shares of Oric Pharmaceuticals in a research note on Monday, May 5th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $19.17.

Institutional Trading of Oric Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC lifted its position in Oric Pharmaceuticals by 56.0% in the first quarter. Jane Street Group LLC now owns 31,198 shares of the company's stock valued at $174,000 after buying an additional 11,198 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Oric Pharmaceuticals by 1,331.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company's stock valued at $2,841,000 after acquiring an additional 473,600 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Oric Pharmaceuticals by 9.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company's stock worth $1,645,000 after acquiring an additional 24,778 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new position in shares of Oric Pharmaceuticals in the 1st quarter worth approximately $1,133,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Oric Pharmaceuticals by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock worth $226,000 after acquiring an additional 3,131 shares during the last quarter. 95.05% of the stock is owned by institutional investors and hedge funds.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.